The computed weighted sum of type I (dark gray) and type II (light gray) errors ( حسب Farrokh Habibzadeh (12256529)

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( حسب Farrokh Habibzadeh (12256529)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Expression of 7 immune genes in <i>Ceratitis capitata</i> inoculated with <i>P</i>. <i>lilacinum</i> for the times analyzed (0h, 24h, 72h, and 144h). حسب Wafa Djobbi (5180810)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Metabolic effects of exposure to AmB in <i>L</i>. <i>mexicana</i> promastigotes cultured in HOMEM and DM. حسب Edubiel A. Alpizar-Sosa (13848145)

"…Each line represents one biological replicate (n = 4). Increase (red) or decrease (blue) in fold-change is relative to untreated cells after treatment with AmB at 5 x their EC₅₀ values for 15 mins. …"

The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases. حسب Simon K. Schnyder (16632244)

Secondary structures contents analysis. حسب Mukesh Kumar (132604)

Contents of PIO Program. حسب Jun-Seo Lim (21161776)

Image_1_Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.TIFF حسب Zhixing Kuang (10809975)

"…Cachexia-inducing factors (CIFs) have been reported in colorectal cancer and pancreatic adenocarcinoma, but their value in diffuse large B-cell lymphoma (DLBCL) requires further genetic research.…"

Table_1_Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.xls حسب Zhixing Kuang (10809975)

"…Cachexia-inducing factors (CIFs) have been reported in colorectal cancer and pancreatic adenocarcinoma, but their value in diffuse large B-cell lymphoma (DLBCL) requires further genetic research.…"

Perturbation on the kinase activity of CaMKII affects sleep duration. حسب Daisuke Tone (9458617)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values). حسب Willem Kaijser (12872371)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Fig 7 - حسب Jacob L. Sheffield (18522351)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. حسب Peiqi Yin (6533747)

Mean values of “I feel bored” item. حسب Ezel Üsten (16548547)